Production of dendritic cells and cytokine-induced killer cells from banked umbilical cord blood samples

Phuc Van Pham, Binh Thanh Vu, Viet Quoc Pham, Phong Minh Le, Hanh Thi Le, Ngoc Kim Phan

Laboratory of Stem Cell Research and Application, University of Science, Viet Nam National University, Ho Chi Minh city, Viet Nam
*Corresponding author: pvphuc@hcmus.edu.vn

Received: 15 Sept 2015 / Accepted: 15 Oct 2015 / Published online: 30 Nov 2015
© The Author(s) 2015. This article is published with open access by BioMedPress (BMP)

Abstract—Umbilical cord blood (UCB) is considered to be a source of hematopoietic stem cells (HSCs). All UCB banks have recently become interested in the isolation and storage of HSCs for the treatment of hematological diseases. However, UCB was also recently confirmed as a source of immune cells for immunotherapy such as dendritic cells (DCs) and cytokine-induced killer cells (CIKs). This study aimed to exploit this source of immune cells in banked UCB samples. After collection of UCB samples, mononuclear cells (MNCs) containing stem cells, progenitor cells, and mature cells were isolated by Ficoll-Hypaque-based centrifugation. The MNCs were subjected to freezing and thawing according to a previously published protocol. The banked MNCs were used to produce DCs and CIKs. To produce DCs, MNCs were induced in RPMI 1640 medium supplemented with GM-CSF (50 ng/ml) and IL-4 (40 ng/ml) for 14 days. To produce CIKs, MNCs were induced in RPMI 1640 medium supplemented with an anti-CD3 monoclonal antibody, IL-3, and GMP-SF for 21–28 days. Both DCs and CIKs were evaluated for their phenotypes and functions according to previously published protocols. The results showed that banked UCB samples can be successfully used to produce functional DCs and CIKs. These samples are valuable sources of immune cells for immunotherapy. The present results suggest that banked UCB samples are useful not only for stem cell isolation, but also for immune cell production.

Keywords—Banked UCB, Stem cells, Immune cells, Dendritic cells, Cytokine-induced killer cells, Immunotherapy

INTRODUCTION

Umbilical cord blood (UCB) is considered to be a source of stem cells, especially hematopoietic stem cells (HSCs). Transplantation of UCB-derived HSCs in the treatment of hematological diseases has been performed for a long time. The first cord blood (CB) transplantation was performed in 1988 in a patient with Fanconi anemia (Gluckman et al., 1989). Banked UCB samples have also been used to treat refractory leukemia at Duke University Medical Center since 1993 (Kurtzberg et al., 1996).

In recent years, many UCB banks have been established around the world. The Netcord group was created in 1998 to establish good practices in UCB storage. The inventory of the Netcord group, a cooperative network of large experienced UCB banks, currently contains more than 200,000 cryopreserved UCB units ready for clinical use (Gluckman, 2009). However, the usage efficiency of these banks is very low. In fact, some private banks only use UCB samples for the donors, while some public banks are faced with seeking HLA-matched samples. For these reasons, some studies and banks have exploited other kinds of stem cells in banked UCB samples. Recently, mesenchymal stem cells (MSCs) were successfully isolated from banked UCBs (Phuc et al., 2012; Phuc et al., 2011).

Fresh UCB samples have been used to produce certain kinds of immune cells for treatment, especially dendritic cells (DCs) (Kim et al., 2015; Liu et al., 2015; Park et al., 2015) and cytokine-induced killer cells (CIKs) (Durrieu et al., 2013; Niu et al., 2011; Zhang et al., 2014). The authors isolated DCs from fresh UCB samples. These DCs clearly exhibited the particular DC phenotypes. The above studies showed that fresh UCB samples comprise a useful source of DCs for clinical
applications. Moreover, some recent publications have shown that mononuclear cells (MNCs) from UCB samples can differentiate into functional CIKs (Durrieu et al., 2013; Niu et al., 2011; Zhang et al., 2014). These CIKs acted as natural killer (NK) cells both in vitro and in vivo (Dalle et al., 2005; Fan et al., 2008; Verneris and Miller, 2009). Furthermore, UCB-derived NK cells express less granzyme and are thus less cytotoxic than peripheral blood-derived NK cells (Wang et al., 2007). These cells were successfully used in certain treatments, such as relapse of acute myeloid leukemia after HLA-mismatched haploidentical stem cell transplantation (Hanley et al., 2010; Ruggeri et al., 2007), esophageal cancer (Wang et al., 2014), hepatocellular carcinoma, renal cell carcinoma, and lung cancer (NCT01914263).

To increase the usage efficiency of banked UCB samples, this study aimed to produce DCs and CIKs from banked UCB samples for immunotherapy. Both DCs and CIKs were produced from UCB-derived MNCs and tested for their phenotypes and in vitro activities.

**MATERIALS AND METHODS**

**UCB collection and MNC isolation**

Umbilical cord blood was collected from a healthy pregnant woman with agreement among the hospital, donor, and laboratory. After the woman gave birth, blood was taken from the fetal cord and treated with the anticoagulant CDPA (Terumo, Japan).

To isolate MNCs, each UCB unit was diluted with phosphate-buffered saline (PBS) at a ratio of 1:1, and 10 ml of the diluted blood was gently loaded onto 25 ml of Ficoll-Hypaque solution (1.077 g/ml; Sigma–Aldrich, St Louis, MO) in a 50-ml tube. After centrifugation at 2,500 rpm for 5 min, MNCs were derived from the interphase layer (above the Ficoll-Hypaque layer), and washed twice with PBS.

**MNC banking and thawing**

The isolated MNCs were resuspended in IMDM cryomedium (Sigma–Aldrich) supplemented with 10% DMSO (Sigma–Aldrich) and 20% fetal bovine serum (FBS) at the density of 10^7–10^8 cells/ml. The sample was transferred to a controlled-rate freezer precooled to 0°C, and sequentially cooled at 1°C/min to −12°C, cooled at 20°C/min to −60°C, warmed at 15°C/min to −18°C, cooled at 1°C/min to −60°C, and cooled at 3°C/min to −100°C. After completion of the freezing protocol, the units were stored in liquid nitrogen.

The sample was rapidly thawed by embedding the cryotube in a 37°C water bath until it was completely liquefied. Immediately afterward, 1 ml of IMDM with 20% FBS and 1% antibiotic/mycotic solution was dropped into the tube. The cell suspension was then transferred to a new 15-ml tube, and centrifuged at 2,500 rpm for 5 min to eliminate the DMSO. The cell pellet was resuspended in culture medium (IMDM plus 20% FBS and 1% antibiotic/mycotic solution) for use in further experiments.

**DC production and characterization**

MNCs were cultured in IMDM medium supplemented with 10% FBS at 37°C for 2–3 h. The adherent cells were cultured to allow their differentiation into DCs according to the following procedures. MNCs were cultured for 9 days in RPMI 1640 medium (Roswell Park Memorial Institute) containing 40 ng/ml interleukin (IL)-4, 50 ng/ml GM-CSF (Santa Cruz Biotechnology, Santa Cruz, CA), and 10% FBS. Fresh medium with added cytokines was additionally provided after a 3-day interval to provide nutrients.

Before and after induction, surface markers of DCs were analyzed by flow cytometry to determine whether DCs were successfully differentiated. Specific primary antibodies were used, such as those against CD14, CD1a, CD80, and CD83 (Santa Cruz Biotechnology). DCs were incubated in 100 μl of PBS containing 5 μl of each monoclonal antibody for 20 min in the dark at room temperature. The cells were then washed three times in PBS and analyzed using FACS flow cytometry (FACSCalibur; Becton Dickinson, Heidelberg, Germany) and Cell Quest software.

**CIK production and characterization**

**Generation of CIKs**

MNCs were cultured in serum-free X-VIVO-15 medium (BioWhittaker, Walkersville, MD) with 1000 U/ml of IFN-γ (Gammakine; Boehringer Ingelheim, Vienna, Austria) added on day 0, 50 ng/ml of anti-CD3 antibody (OKT-3; Janssen-Cilag SpA, Milan, Italy) added on day 1, and 500 U/ml of rhIL-2 included in the medium from day 1 onward. Cell expansion was performed for 21–28 days.

**CIK phenotype analysis**

CIKs were characterized using FITC-conjugated anti-CD3 (SK7 clone) and PE-conjugated anti-CD56 (NCAM16.2 clone) monoclonal antibodies (mAbs)
To analyze the expression of activating receptors on CIKs, the following mAbs were used: anti-NKG2D (BAT221 clone) and anti-NKp30 (A76 clone).

For indirect immunofluorescence staining, cells were incubated with the primary mAbs, followed by PE-conjugated goat anti-mouse IgG1 (Invitrogen, Paisley, UK) or FITC-conjugated goat anti-mouse Ig (Becton Dickinson) secondary antibodies. A FACSCalibur flow cytometer (Becton Dickinson) was used to analyze the samples.

Cell conjugation assay
The target cells (MCF7) were washed, resuspended in 1 ml of PBS supplemented with 1% bovine serum albumin at a final concentration of $5 \times 10^6$ cells/ml, and labeled with the green fluorescent dye carboxyfluorescein succinimidyl ester (CFSE; 2 μM; Sigma–Aldrich) for 10 min at 37°C. Quench-staining was performed on ice for 5 min by adding 5 volumes of ice-cold complete RPMI. The cells were then washed three times with ice-cold PBS containing 1% bovine serum albumin and cultured under appropriate conditions.

For PKH26 staining of CIKs, $10 \times 10^6$ cells were washed in PBS and the cell pellet was resuspended in 500 μL of diluent C (Sigma–Aldrich). The lipophilic red fluorescent dye PKH26 (Sigma–Aldrich) was diluted at a final concentration of 4 μM in 500 μl of diluent C, rapidly added to the cells, and incubated for 5 min at room temperature with occasional agitation. Next, 1 ml of FBS was added and incubated for 1 min at room temperature. The cells were then washed three times in complete culture medium.

A total of $5 \times 10^5$ PKH26-labeled CIKs and $5 \times 10^5$ CFSE-labeled target cells were resuspended in 200 μl of complete medium containing or lacking 1 mM ethylenediaminetetraacetic acid (EDTA; Sigma–Aldrich) and mixed in a 12-mm × 75-mm polystyrene tube (Becton Dickinson Labware, Franklin Lakes, NJ). The effector-target cell mixture was centrifuged at 1,000 rpm for 1 min and incubated at 37°C for specified time periods (5 min and 15 min). The cells were then gently resuspended and analyzed by flow cytometry.

Calcein release cytotoxicity assay
The target cells (MCF7, PC3, and HepG2) were labeled with 3.5 μM calcein-acetoxyethyl ester (calcein-AM; Sigma–Aldrich) for 30 min at 37°C. The labeled cells were then added to 96-well plates at $5 \times 10^3$ cells/well. CIKs were added at different effector-to-target (E:T) ratios. In control samples, the cytotoxicity assay was performed in the presence of 1 mM EDTA. After 4 h, the cells were sedimented by centrifugation. Next, 100 μl of supernatant was collected and determined for calcein release using a fluorescence microplate reader with excitation at 485 nm and emission at 535 nm. The percentage of specific calcein release was calculated using the following formula: percent specific lysis = (test release minus spontaneous release) × 100 / (maximal release minus spontaneous release). Maximal lysis was achieved with 1% Triton X-100.

RESULTS
High percentage of viable cells after thawing
Ten banked UCB samples were thawed and used for induction of DCs and CIKs. Before use, all thawed samples were tested for the percentage of viable cells. The results showed that there were $91.5 \pm 4.56\%$ viable cells in all thawed samples. Each sample was divided into two parts, half for DC induction and half for CIK induction.

Banked UCBs successfully produce functional DCs
Induced cells exhibit the DC phenotype
Thawed UCB-derived MNCs successfully exhibited the DC phenotype. In the adherent culture after 14 days of induction, the cells expressed a similar shape to DCs with many dendrites (Fig. 1). Regarding surface marker expression, the cells expressed DC markers, including CD83 (35.27 ± 18.7%), CD1a (18.9 ± 7.1%), and CD80 (25.88 ± 11.01%), while CD14 was not expressed in CD1a+ cells.

Figure 1. Banked MNCs were successfully induced into dendritic cells. MNCs were thawed from cryoprecopreserved samples (A), were induced into dendritic cells after 7 days (B) and 14 days (C, D).
Dendritic cells and cytokine-induced killer cells from banked umbilical cord blood samples

Pham et al., 2015                                                                                                                                        Biomed Res Ther 2015, 2(11): 402-408

DC candidates can phagocytose FITC-dextran

Phagocytosis is a property of DCs. In this assay, DCs were induced in FITC-dextran-supplemented culture medium. The results revealed that the induced DCs efficiently phagocyted the FITC-dextran. Compared with control cells incubated at 4°C, up to 42.6 ±9.5% of DCs incubated at 37°C could phagocytose FITC-dextran. Meanwhile, at this temperature, about 8.7±24.5% of cells could phagocytose this dextran (Fig. 2).

Figure 2. Flow cytometry analysis of DC phagocytosis using FITC-dextran. The induced DCs phagocytose the FITC-dextran compared with control cells.

DC candidates stimulate allogenic T cells

The induced DCs were mixed with allogenic T cells to evaluate the stimulatory potential of the DCs. The results are shown in Fig. 3. The DCs effectively stimulated the T-cell proliferation in a manner dependent on the ratio of DCs to T cells. The ratio of 1 DC to 10 T cells exhibited the highest stimulating efficacy, and the capacity gradually decreased as the ratio of DCs to T cells decreased. All results were significant compared with the control cells.

Figure 3. DC candidates stimulate the proliferation of allogenic T cells. DC can stimulate the T proliferation on the ratio of DCs to T cells. The ratio of 1 DC to 10 T cells exhibited the highest stimulating efficacy.

Banked UCBs successfully produce functional CIKs

Induced cells exhibit CIK phenotypes

The CIK population with the CD3+CD56+ phenotype was extremely low in the banked UCB samples, and almost of the cells were CD8+. However, after 2 weeks of culture, the percentage of CD3+CD56+ cells had significantly increased to 30.56±7.89%. Besides the CD3+CD56+ population, the cultured cells were almost completely CD3+CD56− cells (45.32±12.82%). The total CD3+ cells accounted for 86.76±45% of the cultured cell population.

CIKs can bind to target cells

Binding of CIKs to target cells is an essential property of CIKs. The assay showed that CIKs were able to bind to target tumor cells. The CIKs were stained with PKH26 and the breast, lung, and liver cancer cells were stained with CFSE. In comparison with control cells (without EDTA), the CIKs bound to the three kinds of tested cancer cells. The percentages of conjugated CIK/cancer cells with double staining (PKH26 and CFSE) were maximal at 15 min after mixing(7.21% at 5 min, 28.92% at 15 min) (Fig. 4).
CIKs can lyse target cells

Lysis of the target cells by CIKs was recorded by calcein assays. The results are shown in Fig. 5. At the E:T ratio of 10:1, the lysis of target cells was highest in all kinds of cancer cells (42%, 38%, and 21% for prostate cancer cells, liver cancer cells, and breast cancer cells, respectively). The percentages of lysed target cells gradually decreased as the E:T ratio decreased. Specifically, for PC3 prostate cancer cells, the percentage of lysis was highest at the E:T ratio of 10:1 (42%), but only 33% at the E:T ratio of 5:1 and 17% at the E:T ratio of 2.5:1. For HepG2 liver cancer cells, the percentage of lysis was highest at the E:T ratio of 10:1 (38%), and gradually decreased to 29% and 15% for E:T ratios of 5:1 and 2.5:1, respectively. Similarly, in MCF7 breast cancer cells, the percentage of lysis was highest at the E:T ratio of 10:1 (21%), and gradually decreased to 17% and 9% at E:T ratios of 5:1, and 2.5:1, respectively.

![Figure 5. CIKs lysed target cells (HepG2, PC3, and MCF7). CIKs successfully lysed the target cells in a manner dependent on the E:T ratio. CIKs could lyse all three kinds of cancer cells (HepG2, red; PC3, blue; MCF7, black). In the control group, EDTA was added to prevent binding of CIKs to the target cells, and the percentage of lysis was very low (white).](image)

DISCUSSION

Immunotherapy is considered to be a promising therapy for certain diseases, especially cancer. In recent years, immune cell-based immunotherapies have rapidly developed in cancer treatment. Some of the immune cells used include DCs and CIKs. The most difficult aspect of immune cell-based treatments is related to their limited sources. The results of this study suggest the possible use of banked UCB samples as sources of DCs and CIKs for immunotherapies.

In the first experiment, we standardized the UCB samples based on their HSC counts. In this manner, 100% of the banked samples were successfully cryopreserved and thawed with a high percentage of viable cells (about 90%). The thawed MNCs could be successfully induced to produce both functional DCs and CIKs.

MNCs comprise complex cocktails of certain kinds of cells like as HSCs, MSCs, EPCs, and monocytes. However, the highest ratio is MNCs, with more than 90%. MNCs are easily induced to differentiate into DCs, as described in previous reports (Kim et al., 2015; Liu et al., 2015; Park et al., 2015). In this study, we also recorded that these cells could be differentiated into functional DCs. After 7 days of induction with cytokines, and 7 days of induction with TNF-α, these cells successfully exhibited the DC phenotype, such as expression of CD1a, CD80, and CD83 and lack of expression of CD14. CD80 and CD83 are important co-stimulators of antigen presentation with T cells. More importantly, the DCs successfully produced IL-12. IL-12 is an essential interleukin for stimulation of T lymphocyte proliferation. In fact, the cell assays showed that the obtained DCs could stimulate T cell proliferation in vitro. In vivo, the role of DCs is important. In particular, after receiving antigens, they present these antigens to T cells as well as B cells. By this process, DCs can trigger T cell proliferation to attack the targets. Phagocytosis is an important characteristic of DCs. The present results showed that the DCs could phagocytose FITC-dextran. In comparisons with DCs derived from fresh UCB samples published previously, the banked UCB-derived DCs clearly exhibited similar phenotypes. In fact, in the study by (Bracho et al., 2003), they successfully produced functional DCs from fresh UCB samples with 31.27 ± 11.7% CD83, 23.4 ± 4.2% CD1a, and 21.97 ± 12.01% CD80. They also recorded that the morphological DCs expressed CD1a, but not CD14. In another study, (Enomoto et al., 2000) compared DCs from fresh peripheral blood and cryo-
preserved PB, and found similar phenotypes between the two DC samples for endocytic capacity, chemotactic migratory capacities, and primary allogeneic T-cell responses.

In the next experiment, we successfully produced CIKs from banked MNC samples. In fact, the induced CIKs exhibited all the particular characteristics of CIKs, including exhibition of the CD3+CD56+ phenotype and binding to some target cells such as MCF7 breast cancer cells, PC3 prostate cancer cells, and HepG2 liver carcinoma cells. In particular, these CIKs could directly lyse the target cells. With these properties, the obtained CIKs were clearly similar to CIKs derived from fresh UCB samples. In fact, (Introna et al., 2006) reported that fresh UCB-derived CIKs showed strong cytotoxic activity against a variety of target tumor cell lines. In addition, (Li et al., 2010) showed that all expanded CB-derived CIKs/NK cells showed cytotoxic activity against the K562 cell line.

**CONCLUSIONS**

UCB has been considered to be a source of HSCs for a long time. However, application of UCB samples to treatment of hematopoietic diseases is limited. The results of the present study suggest that banked UCB samples can act as sources of immune cells, including DCs and CIKs, for immunotherapy. In this study, functional DCs and CIKs were successfully produced from banked UCB samples. The DCs strongly expressed the specific markers of DCs, such as CD40, CD80, CD86, and HLA-DR, phagocytosed an antigen, and efficiently stimulated T cell proliferation. Furthermore, the CIKs strongly inhibited cancer cell proliferation. The present results suggest that banked UCB samples are useful for not only regenerative medicine, but also immunotherapy for cancer treatment.

**Abbreviations**

CD Cluster of Differentiation; CIK Cytokine-induced killer; DC Dendritic cells; HSC Hematopoietic stem cell; MNC Mononuclear cell; UCB Umbilical cord blood

**Acknowledgement**

This study was funded from Viet Nam National University under grant "Optimization of dendritic cell production procedure for clinical application".

**Competing interests**

The authors declare that they have no competing interests.

**Open Access**

This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

Bracho, F., Van De Ven, C., Areman, E., Hughes, R., Davenport, V., Bradley, M., Cai, J., and Cairo, M. (2003). A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs. *Cytotherapy* 5, 349-361.

Dalle, J.H., Menezes, J., Wagner, E., Blagdon, M., Champagne, J., Champagne, M.A., and Duval, M. (2005). Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. *Pediatr Res* 57, 649-655.

Durrieu, L., Dieng, M.M., Le Deist, F., and Haddad, E. (2013). Cord blood-derived and peripheral blood-derived cytokine-induced killer cells are sensitive to Fas-mediated apoptosis. *Biol Blood Marrow Transplant* 19, 1407-1411.

Enomoto, M., Nagayama, H., Sato, K., Xu, Y., Asano, S., and Takahashi, T. (2000). In vitro generation of dendritic cells derived from cryopreserved CD34+ cells mobilized into peripheral blood in lymphoma patients. *Cytotherapy* 2, 95-104.

Fan, Y.Y., Yang, B.Y., and Wu, C.Y. (2008). Phenotypic and functional heterogeneity of natural killer cells from umbilical cord blood mononuclear cells. *Immunol Invest* 37, 79-96.

Gluckman, E. (2009). History of cord blood transplantation. *Bone Marrow Transplant* 44, 621-626.

Gluckman, E., Broxmeyer, H.A., Auerbach, A.D., Friedman, H.S., Douglas, G.W., Devergie, A., Esperou, H., Thierry, D., Socie, G., Lehn, P., et al. (1989). Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med* 321, 1174-1178.

Hanley, P.J., Cruz, C.R., Shpall, E.J., and Bollard, C.M. (2010). Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. *Cytotherapy* 12, 713-720.

Introna, M., Franceschetti, M., Ciocca, A., Borleri, G., Conti, E., Golay, J., and Rambaldi, A. (2006). Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. *Bone marrow transplantation* 38, 621-627.
Kim, S.K., Yun, C.H., and Han, S.H. (2015). Dendritic Cells Differentiated from Human Umbilical Cord Blood-Derived Monocytes Exhibit Tolerogenic Characteristics. *Stem Cells Dev.*

Kurtzberg, J., Laughlin, M., Graham, M.L., Smith, C., Olson, J.F., Halperin, E.C., Ciocci, G., Carrier, C., Stevens, C.E., and Rubinstein, P. (1996). Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. *N Engl J Med* 335, 157-166.

Li, Y., Schmidt Wolf, I.G., Wu, Y.-F., Huang, S.-L., Wei, J., Fang, J., Huang, K., and Zhou, D.-H. (2010). Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. *Anticancer research* 30, 3493-3499.

Liu, Y., Tian, X., Jiang, S., Ren, X., Liu, F., Yang, J., Chen, Y., and Jiang, Y. (2015). Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells. *Cell Immunol.*

Niu, Q., Wang, W., Li, Y., Qin, S., Wang, Y., Wan, G., Guan, J., and Zhu, W. (2011). Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. *Int Immunopharmacol* 11, 449-456.

Park, Y.S., Shin, C., Hwang, H.S., Zenke, M., Han, D.W., Kang, Y.S., Ko, K., Do, Y., and Ko, K. (2015). In vitro generation of functional dendritic cells differentiated from CD34 negative cells isolated from human umbilical cord blood. *Cell Biol Int* 39, 1080-1086.

Phuc, P.V., Ngoc, V.B., Lam, D.H., Tam, N.T., Viet, P.Q., and Ngoc, P.K. (2012). Isolation of three important types of stem cells from the same samples of banked umbilical cord blood. *Cell Tissue Bank* 13, 341-351.

Phuc, P.V., Nhung, T.H., Loan, D.T., Chung, D.C., and Ngoc, P.K. (2011). Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells. *In Vitro Cell Dev Biol Anim* 47, 54-63.

Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., Stern, M., Pende, D., Perruccio, K., Burchielli, E., et al. (2007). Donor natural killer cell allore cognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. *Blood* 110, 433-440.

Verneris, M.R., and Miller, J.S. (2009). The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. *Br J Haematol* 147, 185-191.

Wang, L., Huang, S., Deng, Y., Li, M., Bai, W., Zhong, Z., Zhao, H., Li, Y., Liu, Y., and Wu, M. (2014). Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case report. *Medicine (Baltimore)* 93, e340.

Wang, Y., Xu, H., Zheng, X., Wei, H., Sun, R., and Tian, Z. (2007). High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. *Cell Mol Immunol* 4, 377-382.

Zhang, Q., Wang, L., Luo, C., Shi, Z., Cheng, X., Zhang, Z., Yang, Y., and Zhang, Y. (2014). Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. *Oncol Rep* 32, 2244-2252.

**Cite this article as:**
Pham, P., Vu, B., Pham, V., Le, P., Le, H., & Phan, N. (2015). Production of dendritic cells and cytokine-induced killer cells from banked umbilical cord blood samples. *Biomedical Research And Therapy*, 2(11): 402-408.